Analyzing...
Loading company...
“Operates in Pharmaceuticals — Formulations & API.”
₹9,151 Cr revenue.
COGS 35.3%, employees 25.2%.
“we are moderating our guidance for revenue to be flat for the year and for the EBITDA margins to, moderate to low same, 14.”
“Y o Y decline of three to 4%.”
“I think we'll give more specific guidance later on in the year, but I think we're still holding to the f y thirty numbers.”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | -2.0%▼ | 10.5% |
| ROCE | 2.9%▼ | 13.8% |
| Net Margin | -1.8%▼ | 8.7% |
| EBITDA Margin | 13.3%▼ | 16.0% |
| Debt To Equity | 0.58x▲ | 0.21x |
| Rev Growth 3yr | 8.3%▲ | 5.8% |
Historical valuation data not available.
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue | ₹8,871 Cr -3.1% | ₹9,151 Cr +12.0% | ₹8,171 Cr +15.4% | ₹7,082 Cr |
| Other Income | ₹209 Cr +55.2% | ₹135 Cr -23.1% | ₹175 Cr -22.1% | ₹225 Cr |
| Total Income | ₹9,081 Cr -2.2% | ₹9,286 Cr +11.3% | ₹8,347 Cr +14.2% | ₹7,307 Cr |
| COGS | ₹3,138 Cr -2.9% | ₹3,232 Cr +9.4% | ₹2,954 Cr +9.3% | ₹2,703 Cr |
| ₹9,066 Cr +1.4% | ₹8,944 Cr +9.6% | ₹8,164 Cr +9.2% | ₹7,474 Cr | |
| Profit Before Tax | (₹6 Cr) ↓ Decline | ₹342 Cr +185.2% | ₹120 Cr ↑ Recovery | (₹174 Cr) |
| Exceptional Items | (₹20 Cr) | ₹0.00 Cr +100.0% | (₹63 Cr) -802.2% | (₹7 Cr) |
| ₹217 Cr -32.8% | ₹324 Cr +100.4% | ₹161 Cr +143.5% | ₹66 Cr | |
| Net Profit | (₹164 Cr) ↓ Decline | ₹91 Cr +411.4% | ₹18 Cr ↑ Recovery | (₹186 Cr) |
| Profit (Owners) | (₹164 Cr) ↓ Decline | ₹91 Cr +411.4% | ₹18 Cr ↑ Recovery | (₹186 Cr) |
| Other Comprehensive Income | ₹189 Cr +136.8% | ₹80 Cr +40.7% | ₹57 Cr -67.7% | ₹176 Cr |
| Profit Or Loss Of Associates | ₹60 Cr -17.9% | ₹73 Cr +22.6% | ₹59 Cr +9.5% | ₹54 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Permanent revocation of closure directions for Company s Dahej Site
Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Successful closure of US FDA Inspection at Piramal Pharma s manufacturing facility loca...
Intimation of Schedule of Analyst/ Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Transcript of Conference Call on the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended 31st March, 2026
Contact details of Key Managerial Personnel as required under Regulation 30(5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Audio Recording of Conference Call on the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended 31st March, 2026
Audio Recording of Conference Call on the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended 31st March, 2026
Piramal Pharma Limited has informed the Exchange about Schedule of meet
Piramal Pharma Limited has informed the Exchange about Schedule of Analyst/Investor meet
Contact details of Key Managerial Personnel as required under Regulation 30(5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Revocation of closure direction for Company s Dahej site
Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 FDA inspection
Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015